Regular Article
The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy

https://doi.org/10.1006/scbi.1998.0083Get rights and content

Abstract

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. HER-2/neu has been widely studied in breast cancer. The potential value of HER-2/neu status for the prediction of disease outcome and response to therapy in breast cancer is presented in the light of a series of recently published studies showing a range of impact on the outcome of patients treated with hormonal, cytotoxic and radiation therapies. This review includes the application of serum-based HER-2/neu testing and the use of antibody-based therapies directed against the HER-2/neu protein and their potential to become a new modality for breast cancer treatment.

References (125)

  • EM Berns et al.

    Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

    Gene

    (1995)
  • BG Haffty et al.

    Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study

    Int J Rad Oncol, Biol, Phys

    (1996)
  • DJ Slamon et al.

    Amplification of C-ERB-B2 and aggressive breast tumors

    Science

    (1988)
  • DJ Slamon et al.

    Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/ neu oncogene

    Science

    (1987)
  • MS Berger et al.

    Correlation of c- erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading

    Cancer Res

    (1988)
  • MJ van de Vivjer et al.

    Neu -protein overexpression in breast cancer

    N Engl J Med

    (1988)
  • NH Heintz et al.

    Amplification of the c- erb B-2 oncogene in prognosis of breast adenocarcinoma

    Arch Pathol Lab Med

    (1990)
  • H Tsuda et al.

    Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma

    A retrospective analysis of

    (1990)
  • A Borg et al.

    HER-2/neu amplification predicts poor survival in node-positive breast cancer

    Cancer Res

    (1990)
  • S Paik et al.

    Pathologic findings from the nations surgical adjuvant breast and bowel project: Prognostic significance of erb B2 protein overexpression in primary breast cancer

    J Clin Oncol

    (1990)
  • H Battifora et al.

    Immunohistochemical assay of neu/ c- erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases

    Modern Pathol

    (1991)
  • OP Kallioniemi et al.

    Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer

    Int J Cancer

    (1991)
  • GM Clark et al.

    Follow-up study of HER-2/neu amplification in primary breast cancer

    Cancer Res

    (1991)
  • C Lovekin et al.

    C-erb B2 oncoprotein expression in primary and advanced breast cancer

    Br J Cancer

    (1991)
  • AH McCann et al.

    Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer

    Cancer Res

    (1991)
  • R Dykens et al.

    Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11

    J Pathol

    (1991)
  • F Rilke et al.

    Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors

    Int J Cancer

    (1991)
  • J Winstanley et al.

    The long term prognostic significance of C-erb B2 in primary breast cancer

    Br J Cancer

    (1991)
  • SM O'Reilly et al.

    The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer

    Br J Cancer

    (1991)
  • MC Paterson et al.

    Correlation between C-erb B2 amplification and risk of recurrent disease in node-negative breast cancer

    Cancer Res

    (1991)
  • S Toikkanen et al.

    Prognostic significance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up

    J Clin Oncol

    (1992)
  • R Molina et al.

    Expression of HER-2/neu oncoprotein in breast cancer: A comparison of immunohistochemical and western blot techniques

    Anticancer Res

    (1992)
  • M Noguchi et al.

    c- erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer

    Cancer

    (1992)
  • DC Allred et al.

    HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma

    J Clin Oncol

    (1992)
  • J Babiak et al.

    Significance of c- erb B-2 amplification in DNA aneuploidy

    Analysis in

    (1992)
  • RK Tiwari et al.

    HER-2/ neu amplification and overexpression in primary human breast cancer is associated with early metastasis

    Anticancer Res

    (1992)
  • BA Gusterson et al.

    Prognostic importance of C-erb B2 expression in breast cancer

    J Clin Oncol

    (1992)
  • S Bianchi et al.

    Prognostic significance of C-erb B2 expression in node negative breast cancer

    Br J Cancer

    (1993)
  • MF Press et al.

    Her-2/ neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease

    Cancer Res

    (1993)
  • R Seshadri et al.

    Clinical sign ificance of Her-2/ neu oncogene amplification in primary breast cancer

    J Clin Oncol

    (1993)
  • F Descotes et al.

    Human breast cancer: Correlation study between Her-2/ neu amplification and prognostic factors in an unselected population

    Anticancer Res

    (1993)
  • M Giai et al.

    Prognostic and predictive relevance of C-erb B2 and ras expression in node positive and negative breast cancer

    Anticancer Res

    (1994)
  • HB Muss et al.

    Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer

    N Engl J Med

    (1994)
  • B Tetu et al.

    Prognostic significance of Her-2/ neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

    Cancer

    (1994)
  • LC Hartmann et al.

    Prognostic value of CerbB2 overexpression in axillary lymph node positive breast cancer

    Results from a randomized adjuvant treatment protocol. Cancer

    (1994)
  • J Jacquemier et al.

    Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression

    Anticancer Res

    (1994)
  • JR Marks et al.

    Overexpression of p53 and Her-2/ neu proteins as prognostic markers in early stage breast cancer

    Ann Surg

    (1994)
  • PP Rosen et al.

    Immunohistochemical detection of Her-2/ neu expression in patients with axillary lymph node-negative breast carcinoma

    A study of epidemiologic risk factors, histologic features and prognosis. Cancer

    (1995)
  • N Quenel et al.

    The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases

    Breast Cancer Res Treat

    (1995)
  • AS Sundblad et al.

    Carcinoembryonic expression in stages I and II breast cancer; its relationship with clinicopathologic factors

    Hum Pathol

    (1996)
  • Cited by (176)

    • Feature screening for multiple responses

      2023, Journal of Multivariate Analysis
    • Glycolytic activity in breast cancer using <sup>18</sup>F-FDG PET/CT as prognostic predictor: A molecular phenotype approach

      2016, Revista Espanola de Medicina Nuclear e Imagen Molecular
      Citation Excerpt :

      No significant association was found about histopathologic lymph node involvement with OS and DFS, both in univariate and multivariate analysis (p = 0.342 and p = 0.342 for OS and p = 0.365 and p = 0.568 for DFS). In BC some groups of tumors display distinctive epidemiological phenotypes and molecular features with higher relapse rates and a poor prognosis, as basal or triple negative and HER-2 overexpression tumors.8–11 In the present work we decided to join both molecular phenotypes in the high-risk category and observed that this group of patients displayed a lower OS and DFS in 5 years comparing to the other groups (Table 5).

    • Lipid metabolism and cancer progression: The missing target in metastatic cancer treatment

      2015, Journal of Applied Biomedicine
      Citation Excerpt :

      For instance, leptin affects the synthesis and/or function of estrogen receptor alpha (ERα), vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2 (HER2) (Garofalo et al., 2006; Surmacz, 2007). HER2 is a tyrosine kinase that is amplified in 25–30% of breast tumors and it's over expression often correlates with a more aggressive, metastatic phenotype and worse prognosis (Ross and Fletcher, 1999; Yarden and Sliwkowski, 2001). In fact, data from clinical studies clearly revealed a correlation between presence of leptin and ObR (the overall association was about 93%) in both HER2-positive and HER2-negative subgroups in 59 breast cancer cases (Fiorio et al., 2008).

    • Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis

      2014, Cell Reports
      Citation Excerpt :

      The ErbB family of tyrosine kinase receptors plays a key role in breast carcinogenesis through complex signaling networks made of multiple heterodimeric combinations of ErbB receptors (Eccles, 2011). Although having no identified ligand, ErbB2 is amplified and overexpressed in high-grade ductal carcinoma (Ross and Fletcher, 1999) and in high-grade inflammatory breast cancer (Charafe-Jauffret et al., 2004) thereby being largely involved in the induction and development of the malignant transformation (Freudenberg et al., 2009). Several studies revealed the importance of the dimeric status of ErbB2 triggering signaling cascades including the MAPK and PI3K/Akt pathways (Freudenberg et al., 2009).

    View all citing articles on Scopus

    Unspecified

    View full text